Phase 1 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to give their signed agreement to participate in the trial.
- People who are 18 years of age or older at the time of signing the consent form.
- Men who have been diagnosed with prostate adenocarcinoma (a specific type of prostate cancer) confirmed by a tissue test, where the cancer is either high-risk locally advanced (based on PSA level above 20, a high aggressiveness score, or tumour size) or locally advanced with any PSA or aggressiveness score but with a larger or more spread tumour in the local area.
- People whose blood and organ function test results at screening fall within acceptable ranges, including healthy enough levels of platelets, haemoglobin, white blood cells, neutrophils, liver enzymes, bilirubin, and kidney function.
- People with a general health and activity level rated 0, 1, or 2 on a standard oncology scale (meaning able to carry out at least some daily activities, with or without some limitations).
- People whom the treating doctor considers to have a life expectancy of at least 6 months.
- Men who are willing to use contraception during treatment and for 3 months after the last dose when having sex with a pregnant woman or a woman who could become pregnant. Female partners of male participants who could become pregnant should also use a highly effective form of contraception.
Who may not be able to join:
- People who have had a major heart event — such as a heart attack, new or worsening heart failure, or a stroke — within the past 6 months.
- People who are currently participating in another clinical trial involving an experimental treatment.
- People whose cancer has spread to distant parts of the body (distant metastases).
- People who have another active cancer that currently requires treatment.
- People who have had a serious allergic reaction to a medication that is chemically or biologically similar to any of the study drugs.
- People who have another illness that is not well controlled.
- People who are unable to swallow pills.
- People who are not suitable candidates for surgery or radiation therapy.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 405-271-8777
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of patient experiencing dose limiting toxicity (DLT) and tolerable dose of relugolix and enzalutamide combination; Proportion of patients experiencing Pathologic Complete Response (pCR) and Minimal Residual Disease (MRD) in Neoadjuvant ADT with the combination of Relugolix and Enzalutamide
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.